JP2023549266A - Ｒｎａを含むｌｎｐ組成物ならびにそれを調製、貯蔵および使用する方法 - Google Patents

Ｒｎａを含むｌｎｐ組成物ならびにそれを調製、貯蔵および使用する方法 Download PDF

Info

Publication number
JP2023549266A
JP2023549266A JP2023528666A JP2023528666A JP2023549266A JP 2023549266 A JP2023549266 A JP 2023549266A JP 2023528666 A JP2023528666 A JP 2023528666A JP 2023528666 A JP2023528666 A JP 2023528666A JP 2023549266 A JP2023549266 A JP 2023549266A
Authority
JP
Japan
Prior art keywords
composition
rna
anions
lipid
final
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528666A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022101470A5 (https=
JP2023549266A5 (https=
Inventor
パンツナー，シュテッフェン
シャヒン，ウール
クレイヘル，ヨリト－ヤン
タンキ，カウシク
スボド バトナガル，バクル
ダルヴァリ，ラミン
ルトラ，スミト
チェサロフ，セルゲイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biontech SE
Original Assignee
Biontech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2021/059460 external-priority patent/WO2022218503A1/en
Application filed by Biontech SE filed Critical Biontech SE
Publication of JP2023549266A publication Critical patent/JP2023549266A/ja
Publication of JPWO2022101470A5 publication Critical patent/JPWO2022101470A5/ja
Publication of JP2023549266A5 publication Critical patent/JP2023549266A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023528666A 2020-11-16 2021-11-15 Ｒｎａを含むｌｎｐ組成物ならびにそれを調製、貯蔵および使用する方法 Pending JP2023549266A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202063114478P 2020-11-16 2020-11-16
US63/114,478 2020-11-16
US202063115588P 2020-11-18 2020-11-18
US202063115128P 2020-11-18 2020-11-18
EP2020082602 2020-11-18
US63/115,588 2020-11-18
US63/115,128 2020-11-18
EPPCT/EP2020/082602 2020-11-18
US202163135723P 2021-01-10 2021-01-10
US63/135,723 2021-01-10
US202163149372P 2021-02-15 2021-02-15
US63/149,372 2021-02-15
EPPCT/EP2021/059460 2021-04-12
PCT/EP2021/059460 WO2022218503A1 (en) 2021-04-12 2021-04-12 Lnp compositions comprising rna and methods for preparing, storing and using the same
PCT/EP2021/081675 WO2022101470A1 (en) 2020-11-16 2021-11-15 Lnp compositions comprising rna and methods for preparing, storing and using the same

Publications (3)

Publication Number Publication Date
JP2023549266A true JP2023549266A (ja) 2023-11-22
JPWO2022101470A5 JPWO2022101470A5 (https=) 2024-11-22
JP2023549266A5 JP2023549266A5 (https=) 2024-11-22

Family

ID=78621901

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528666A Pending JP2023549266A (ja) 2020-11-16 2021-11-15 Ｒｎａを含むｌｎｐ組成物ならびにそれを調製、貯蔵および使用する方法

Country Status (10)

Country Link
US (1) US20230414747A1 (https=)
EP (1) EP4243788A1 (https=)
JP (1) JP2023549266A (https=)
KR (1) KR20230121752A (https=)
AU (1) AU2021379090A1 (https=)
CA (1) CA3198742A1 (https=)
IL (1) IL302771A (https=)
MX (1) MX2023005696A (https=)
TW (1) TW202237148A (https=)
WO (1) WO2022101470A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4414109A1 (en) 2021-09-24 2024-08-14 Cosmo Koki Co., Ltd. Piercing machine

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
CN118488834A (zh) * 2021-11-23 2024-08-13 赛欧生物医药股份有限公司 细菌源性脂质组合物和其用途
US20250302747A1 (en) * 2022-06-08 2025-10-02 Academia Sinica Lipids, nanoparticles comprising the same and uses thereof
CN114989182B (zh) * 2022-06-23 2023-06-23 尧唐(上海)生物科技有限公司 脂质化合物、包含其的组合物及应用
EP4604927A1 (en) * 2022-10-17 2025-08-27 Agilent Technologies, Inc. Methods of analyzing lipid nanoparticles in physiological fluids
EP4637787A2 (en) * 2022-12-20 2025-10-29 Seqirus Inc. Lipid nanoparticle composition
WO2024131874A1 (en) * 2022-12-21 2024-06-27 Abogen Biosciences (Shanghai) Co., Ltd. Polynucleotides encoding cd19/cd3 bispecific antibodies
WO2024193827A1 (en) * 2023-03-23 2024-09-26 BioNTech SE Stabilized nucleic acid compositions and methods for preparing, storing and using the same
WO2024203660A1 (ja) * 2023-03-29 2024-10-03 国立大学法人東北大学 核酸内封脂質ナノ粒子の製造方法
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025068553A1 (en) 2023-09-28 2025-04-03 Universität Basel Catalytic moieties for treating cancer
WO2025080672A1 (en) * 2023-10-09 2025-04-17 The Trustees Of The University Of Pennsylvania Immune cell targeted delivery vehicles and methods of use thereof
GB202404607D0 (en) * 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019525901A (ja) * 2016-06-14 2019-09-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 脂質ナノ粒子の安定化製剤
JP2023552678A (ja) * 2020-11-16 2023-12-19 ビオンテック・ソシエタス・エウロパエア 粒子およびｍＲＮＡを含む医薬組成物ならびにそれを調製および貯蔵する方法
JP2023552681A (ja) * 2020-11-16 2023-12-19 ビオンテック・ソシエタス・エウロパエア 製剤安定化の向上および凍結乾燥プロセスの改善

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
US20180303925A1 (en) 2015-04-27 2018-10-25 The Trustees Of The University Of Pennsylvania Nucleoside-Modified RNA For Inducing an Adaptive Immune Response
IL307179A (en) * 2015-10-28 2023-11-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
BR112018069417A2 (pt) 2016-04-22 2019-01-22 Biontech Rna Pharmaceuticals Gmbh método para fornecer rna fita simples e ssrna
BR112019008481A2 (pt) 2016-10-26 2020-03-03 Curevac Ag Vacinas de mrna de nanopartículas lipídicas
WO2020072605A1 (en) * 2018-10-02 2020-04-09 Intellia Therapeutics, Inc. Ionizable amine lipids
JP2023511633A (ja) * 2020-01-28 2023-03-20 モデルナティエックス インコーポレイテッド コロナウイルスｒｎａワクチン
EP3865122A1 (en) * 2020-02-11 2021-08-18 Pantherna Therapeutics GmbH Lipid composition and use thereof for delivery of a therapeutically active agent to endothelium

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019525901A (ja) * 2016-06-14 2019-09-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 脂質ナノ粒子の安定化製剤
JP2023552678A (ja) * 2020-11-16 2023-12-19 ビオンテック・ソシエタス・エウロパエア 粒子およびｍＲＮＡを含む医薬組成物ならびにそれを調製および貯蔵する方法
JP2023552681A (ja) * 2020-11-16 2023-12-19 ビオンテック・ソシエタス・エウロパエア 製剤安定化の向上および凍結乾燥プロセスの改善

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4414109A1 (en) 2021-09-24 2024-08-14 Cosmo Koki Co., Ltd. Piercing machine

Also Published As

Publication number Publication date
KR20230121752A (ko) 2023-08-21
AU2021379090A9 (en) 2025-01-09
EP4243788A1 (en) 2023-09-20
US20230414747A1 (en) 2023-12-28
TW202237148A (zh) 2022-10-01
IL302771A (en) 2023-07-01
WO2022101470A1 (en) 2022-05-19
MX2023005696A (es) 2023-05-29
AU2021379090A1 (en) 2023-06-15
CA3198742A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
JP2023549266A (ja) Ｒｎａを含むｌｎｐ組成物ならびにそれを調製、貯蔵および使用する方法
JP2023552678A (ja) 粒子およびｍＲＮＡを含む医薬組成物ならびにそれを調製および貯蔵する方法
JP7446527B2 (ja) コード核酸の治療可能性についての効力アッセイ
US20240408032A1 (en) Lipid-based rna formulations suitable for therapy
CN119156205A (zh) 用于施用rna的基于脂质的制剂
CN116829134A (zh) 包含rna的lnp组合物及其制备、储存和使用方法
WO2022218503A1 (en) Lnp compositions comprising rna and methods for preparing, storing and using the same
JP2025514649A (ja) 無機ポリリン酸などの多価アニオンを含む核酸組成物ならびにその製造、保存および使用のための方法
JP2026508330A (ja) 多重コーディング核酸のリンカー配列効力アッセイ
US20240226132A1 (en) Rna compositions comprising a buffer substance and methods for preparing, storing and using the same
CN120712350A (zh) 用于药物用途的rna制剂
CN116669709A (zh) 包含颗粒和mRNA的药物组合物及其制备和储存的方法
HK40100852A (zh) 包含rna的lnp组合物及其制备、储存和使用方法
HK40099059A (zh) 包含颗粒和mrna的药物组合物及其制备和储存的方法
WO2025223684A1 (en) Methods and compositions for stimulating immune response
CN118176209A (zh) 涉及用于抗原疫苗接种的非免疫原性rna和pd-1轴结合拮抗剂的治疗
CN117615752A (zh) 包含缓冲物质的rna组合物及其制备、储存和使用方法
CN118804763A (zh) 用于施用不同剂量rna的组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260319